Campath-1H does not alter bone marrow cell regulatory function

Yide Jin, Laphalle Fuller, Anne Rosen, Gaetano Ciancio, George W Burke, Camillo Ricordi, Andreas G. Tzakis, Joshua Miller, Violet Esquenazi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We have previously reported in laboratory volunteers (in vitro) and renal transplant recipients (ex vivo) that bone marrow cells (BMC) are potent downregulators of the immune response. Also, the use of alemtuzumab (Campath-1H, C1H) for immunodepletion is associated with the most potent lasting effects yet seen on T-cell immunity in renal transplantation. We questioned whether the administration of C1H to kidney allograft recipients of donor bone marrow cell (DBMC) infusions would lead to stronger or weaker immunoregulatory effects. Human BMC depleted of T cells (nT-BMC) were either untreated or treated with C1H and rabbit complement and compared for their ability to downregulate autologous or allogeneic T-cell responses and to generate T regulatory (T reg) cells. The proliferative responses to anti-CD3 monoclonal antibody of T cells derived from cocultures with C1H-treated or untreated autologous nT-BMC were equally suppressed, i.e., an equivalent alteration in CD3 complex signaling, not regained by the addition of interleukin 2. Adenosine triphosphate levels were also markedly reduced in T cells both from C1H-treated and untreated nT-BMC cocultures. The ability of C1H-treated or untreated nT-BMC to suppress autologous T-cell cytotoxic function was also equivalent, with a marked, but equivalent, capacity to induce CD4/CD25high T regs from CD3 + cells, which effectively downregulated cytotoxic T cells. To mimic the clinical infusion of DBMC into (allogeneic) recipients, peripheral blood mononuclear cells were also cultured with allogeneic C1H-treated and untreated nT-BMC. T cells derived from these cultures secondarily stimulated with the same-donor mature antigen-presenting cells exhibited suppressed cytotoxicity by 85% and 54%, respectively. These in vitro studies suggest that C1H does not abrogate BMC immunoregulation and thus may allow its lympho-depleting effect to be synergistic.

Original languageEnglish
Pages (from-to)637-643
Number of pages7
JournalHuman Immunology
Volume66
Issue number6
DOIs
StatePublished - Jun 1 2005

Fingerprint

Bone Marrow Cells
T-Lymphocytes
Coculture Techniques
Down-Regulation
alemtuzumab
Tissue Donors
CD3 Antigens
Kidney
Antigen-Presenting Cells
Regulatory T-Lymphocytes
Kidney Transplantation
Interleukin-2
Allografts
Volunteers
Immunity
Blood Cells
Cell Culture Techniques
Adenosine Triphosphate
Monoclonal Antibodies
Rabbits

Keywords

  • Bone marrow antigen-presenting cell
  • Campath-1H
  • Regulatory function

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Campath-1H does not alter bone marrow cell regulatory function. / Jin, Yide; Fuller, Laphalle; Rosen, Anne; Ciancio, Gaetano; Burke, George W; Ricordi, Camillo; Tzakis, Andreas G.; Miller, Joshua; Esquenazi, Violet.

In: Human Immunology, Vol. 66, No. 6, 01.06.2005, p. 637-643.

Research output: Contribution to journalArticle

Jin, Y, Fuller, L, Rosen, A, Ciancio, G, Burke, GW, Ricordi, C, Tzakis, AG, Miller, J & Esquenazi, V 2005, 'Campath-1H does not alter bone marrow cell regulatory function', Human Immunology, vol. 66, no. 6, pp. 637-643. https://doi.org/10.1016/j.humimm.2005.03.005
Jin, Yide ; Fuller, Laphalle ; Rosen, Anne ; Ciancio, Gaetano ; Burke, George W ; Ricordi, Camillo ; Tzakis, Andreas G. ; Miller, Joshua ; Esquenazi, Violet. / Campath-1H does not alter bone marrow cell regulatory function. In: Human Immunology. 2005 ; Vol. 66, No. 6. pp. 637-643.
@article{5ce553c877ec49d09326b339dc3ca62d,
title = "Campath-1H does not alter bone marrow cell regulatory function",
abstract = "We have previously reported in laboratory volunteers (in vitro) and renal transplant recipients (ex vivo) that bone marrow cells (BMC) are potent downregulators of the immune response. Also, the use of alemtuzumab (Campath-1H, C1H) for immunodepletion is associated with the most potent lasting effects yet seen on T-cell immunity in renal transplantation. We questioned whether the administration of C1H to kidney allograft recipients of donor bone marrow cell (DBMC) infusions would lead to stronger or weaker immunoregulatory effects. Human BMC depleted of T cells (nT-BMC) were either untreated or treated with C1H and rabbit complement and compared for their ability to downregulate autologous or allogeneic T-cell responses and to generate T regulatory (T reg) cells. The proliferative responses to anti-CD3 monoclonal antibody of T cells derived from cocultures with C1H-treated or untreated autologous nT-BMC were equally suppressed, i.e., an equivalent alteration in CD3 complex signaling, not regained by the addition of interleukin 2. Adenosine triphosphate levels were also markedly reduced in T cells both from C1H-treated and untreated nT-BMC cocultures. The ability of C1H-treated or untreated nT-BMC to suppress autologous T-cell cytotoxic function was also equivalent, with a marked, but equivalent, capacity to induce CD4/CD25high T regs from CD3 + cells, which effectively downregulated cytotoxic T cells. To mimic the clinical infusion of DBMC into (allogeneic) recipients, peripheral blood mononuclear cells were also cultured with allogeneic C1H-treated and untreated nT-BMC. T cells derived from these cultures secondarily stimulated with the same-donor mature antigen-presenting cells exhibited suppressed cytotoxicity by 85{\%} and 54{\%}, respectively. These in vitro studies suggest that C1H does not abrogate BMC immunoregulation and thus may allow its lympho-depleting effect to be synergistic.",
keywords = "Bone marrow antigen-presenting cell, Campath-1H, Regulatory function",
author = "Yide Jin and Laphalle Fuller and Anne Rosen and Gaetano Ciancio and Burke, {George W} and Camillo Ricordi and Tzakis, {Andreas G.} and Joshua Miller and Violet Esquenazi",
year = "2005",
month = "6",
day = "1",
doi = "10.1016/j.humimm.2005.03.005",
language = "English",
volume = "66",
pages = "637--643",
journal = "Human Immunology",
issn = "0198-8859",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Campath-1H does not alter bone marrow cell regulatory function

AU - Jin, Yide

AU - Fuller, Laphalle

AU - Rosen, Anne

AU - Ciancio, Gaetano

AU - Burke, George W

AU - Ricordi, Camillo

AU - Tzakis, Andreas G.

AU - Miller, Joshua

AU - Esquenazi, Violet

PY - 2005/6/1

Y1 - 2005/6/1

N2 - We have previously reported in laboratory volunteers (in vitro) and renal transplant recipients (ex vivo) that bone marrow cells (BMC) are potent downregulators of the immune response. Also, the use of alemtuzumab (Campath-1H, C1H) for immunodepletion is associated with the most potent lasting effects yet seen on T-cell immunity in renal transplantation. We questioned whether the administration of C1H to kidney allograft recipients of donor bone marrow cell (DBMC) infusions would lead to stronger or weaker immunoregulatory effects. Human BMC depleted of T cells (nT-BMC) were either untreated or treated with C1H and rabbit complement and compared for their ability to downregulate autologous or allogeneic T-cell responses and to generate T regulatory (T reg) cells. The proliferative responses to anti-CD3 monoclonal antibody of T cells derived from cocultures with C1H-treated or untreated autologous nT-BMC were equally suppressed, i.e., an equivalent alteration in CD3 complex signaling, not regained by the addition of interleukin 2. Adenosine triphosphate levels were also markedly reduced in T cells both from C1H-treated and untreated nT-BMC cocultures. The ability of C1H-treated or untreated nT-BMC to suppress autologous T-cell cytotoxic function was also equivalent, with a marked, but equivalent, capacity to induce CD4/CD25high T regs from CD3 + cells, which effectively downregulated cytotoxic T cells. To mimic the clinical infusion of DBMC into (allogeneic) recipients, peripheral blood mononuclear cells were also cultured with allogeneic C1H-treated and untreated nT-BMC. T cells derived from these cultures secondarily stimulated with the same-donor mature antigen-presenting cells exhibited suppressed cytotoxicity by 85% and 54%, respectively. These in vitro studies suggest that C1H does not abrogate BMC immunoregulation and thus may allow its lympho-depleting effect to be synergistic.

AB - We have previously reported in laboratory volunteers (in vitro) and renal transplant recipients (ex vivo) that bone marrow cells (BMC) are potent downregulators of the immune response. Also, the use of alemtuzumab (Campath-1H, C1H) for immunodepletion is associated with the most potent lasting effects yet seen on T-cell immunity in renal transplantation. We questioned whether the administration of C1H to kidney allograft recipients of donor bone marrow cell (DBMC) infusions would lead to stronger or weaker immunoregulatory effects. Human BMC depleted of T cells (nT-BMC) were either untreated or treated with C1H and rabbit complement and compared for their ability to downregulate autologous or allogeneic T-cell responses and to generate T regulatory (T reg) cells. The proliferative responses to anti-CD3 monoclonal antibody of T cells derived from cocultures with C1H-treated or untreated autologous nT-BMC were equally suppressed, i.e., an equivalent alteration in CD3 complex signaling, not regained by the addition of interleukin 2. Adenosine triphosphate levels were also markedly reduced in T cells both from C1H-treated and untreated nT-BMC cocultures. The ability of C1H-treated or untreated nT-BMC to suppress autologous T-cell cytotoxic function was also equivalent, with a marked, but equivalent, capacity to induce CD4/CD25high T regs from CD3 + cells, which effectively downregulated cytotoxic T cells. To mimic the clinical infusion of DBMC into (allogeneic) recipients, peripheral blood mononuclear cells were also cultured with allogeneic C1H-treated and untreated nT-BMC. T cells derived from these cultures secondarily stimulated with the same-donor mature antigen-presenting cells exhibited suppressed cytotoxicity by 85% and 54%, respectively. These in vitro studies suggest that C1H does not abrogate BMC immunoregulation and thus may allow its lympho-depleting effect to be synergistic.

KW - Bone marrow antigen-presenting cell

KW - Campath-1H

KW - Regulatory function

UR - http://www.scopus.com/inward/record.url?scp=21544459075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21544459075&partnerID=8YFLogxK

U2 - 10.1016/j.humimm.2005.03.005

DO - 10.1016/j.humimm.2005.03.005

M3 - Article

VL - 66

SP - 637

EP - 643

JO - Human Immunology

JF - Human Immunology

SN - 0198-8859

IS - 6

ER -